Medical Radiology and Radiation Safety. 2025. Vol. 70. № 4
DOI:10.33266/1024-6177-2025-70-4-102-105
E.V. Efanova1, 2, Zh.A. Startseva3, S.A. Fursov1, 2, A.L. Chernyshova1, 4,
O.A. Tkachuk1, 2
Features of Radiation Reactions in Patients with Prostate Cancer
with Metabolic Syndrome on the Background of Thermoradiotherapy
1 Novosibirsk State Medical University, Novosibirsk, Russia
2 Novosibirsk Regional Clinical Oncological Dispensary, Novosibirsk, Russia
3 Cancer Research Institute of Tomsk National Research Medical Center, Tomsk. Russia
4 E.N. Meshalkin National Medical Research Center, Novosibirsk, Russia
Contact person: Ekaterina V. Efanova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ANNOTATION
Background: Prostate cancer (PC) is one of the most common cancers in men. According to the statistics of the Russian Federation for 2023, prostate cancer ranks 1st among malignant neoplasms in men (19.1 %) and 3rd (8.3 %) in the structure of mortality from malignant neoplasms in the male population. One of the main methods of treating prostate cancer is remote radiation therapy, with a combination of radiotherapy and local hyperthermia, the term thermoradotherapy is used. There has been a steady increase in patients with metabolic syndrome (MS) among prostate cancer patients. Given the complex hormonal and metabolic changes in MS, it is currently believed that this syndrome is a potential risk factor for an unfavorable prognosis in the treatment of prostate cancer.
Purpose: to evaluate the effect of metabolic syndrome in patients with prostate malignancy on the frequency and severity of adverse events during thermoradotherapy.
Material and methods: This non-randomized comparative study involved 60 patients diagnosed with prostate cancer (adenocarcinoma) T3-T4N0M0 who received remote radiation therapy using volume modulated therapy (VMAT) with irradiation of the prostate gland, seminal vesicles, and pelvic lymph nodes to a total focal dose (SOD) of 80/80/50 Gy in the mode 5 times a week, 28 sessions, on Electa linear electron accelerators Versa HD (Great Britain), photon beam of 6 Mev energy with local hyperthermia radio modification on a Celsius TCS device (Germany) according to the scheme: 2 times a week, 8–10 procedures in total 2 hours before radiation therapy, heating duration 40–60 minutes at a temperature of 40–42 °C. The study group included 30 people who received thermoradotherapy and were diagnosed with metabolic syndrome (according to the criteria of the IDF in 2009) before starting treatment. The control group consisted of 30 patients undergoing thermoradotherapy without a history of metabolic syndrome.
Results and discussion: Analysis of these patient groups shows that in the category of prostate cancer patients with metabolic syndrome, compared with the control group, more pronounced radiation reactions prevail, such as radioepitheliitis on the skin at the site of irradiation and nocturia. Metabolic changes cause disorders of lymphatic and circulatory microcirculation, skin repair processes; abdominal obesity leads to increased intra-abdominal pressure, which increases the frequency of urination at night.
Conclusion: Prostate cancer patients with metabolic syndrome receiving thermoradotherapy require great attention from doctors due to the increased risk of developing severe radiation reactions. In this regard, further research in this area is necessary, which makes an unconditional contribution to improving the effectiveness of treatment in this category of patients.
Keywords: prostate cancer, radiation therapy, local hyperthermia, thermoradotherapy, metabolic syndrome, radiation reactions
For citation: Efanova EV, Startseva ZhA, Fursov SA, Chernyshova AL, Tkachuk OA. Features of Radiation Reactions in Patients with Prostate Cancer with Metabolic Syndrome on the Background of Thermoradiotherapy. Medical Radiology and Radiation Safety. 2025;70(4):102–105. (In Russian). DOI:10.33266/1024-6177-2025-70-4-102-105
References
1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennyye Novoobrazovaniya v Rossii v 2023 Godu (Zabolevayemost’ i Smertnost’) = Malignant Neoplasms in Russia in 2023 (Morbidity and Mortality). Moscow, Moskovskiy Nauchno-Issledovatel’skiy Onkologicheskiy Institut Imeni P.A.Gertsena Publ., 2023. 276 p. (In Russ.).
2. Kipriyanov Ye.A. Gipertermiya kak Komponent Kompleksnogo Lecheniya Bol’nykh Rakom Predstatel’noy Zhelezy = Hyperthermia as a Component of Complex Treatment of Patients with Prostate Cancer. Doctor’s Thesis (Med.). Moscow Publ., 2009. 154 p. (In Russ.).
3. Nosov D.A., Volkova M.I., Gladkov O.A., Karabina Ye.V., Krylov V.V., Matveyev V.B., et al. Practical Recommendations for drug Treatment of Prostate Cancer. Prakticheskiye Rekomendatsii RUSSCO = Practical Recommendations RUSSCO. 2023;13:640-660 (In Russ.). doi: 10.18027/2224-5057-2021-11-3s2-33 (In Russ.).
4. Peshkov M.N., Peshkova G.P., Reshetov I.V. Metabolic Changes in Patients with Prostate Cancer during Androgen Deprivation Therapy. Sakharnyy Diabet = Diabetes Mellitus. 2020;23;2:192-200 (In Russ.).
5. Moon S., Chung H.S., Yu J.M., Ko K.J., Choi D.K., Kwon O., Lee Y.G., Cho S.T. The Association Between Obesity and the Nocturia in the U.S. Population. Int Neurourol J. 2019 Jun;23;2:169-176.
6. Knights A.J., Funnell A.P., Pearson R.C., et al. Adipokines and Insulin Action: a Sensitive Issue. Adipocyte. 2014;3;2:88-96.
7. Losano G., Folino A., Rastaldo R. Role of Three Adipokines in Metabolic Syndrome. Pol Arch Med Wewn. 2016;126;4:219-221.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. E.V. Efanova – study design, patient selection according to inclusion criteria, patient management, filling out primary documentation, writing the manuscript; Z.A. Startseva – general management of the study, proofreading the article; S.A. Fursov – general management of the study, proofreading the article; A.L. Chernyshova –proofreading the article; O.A. Tkachuk – study design, proofreading the article. All authors read and approved the final version before publication.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.03.2025. Accepted for publication: 25.04.2025.